IBO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
21.0K
+600.0%
3.0K
-57.1%
7.0K
+0.0%
7.0K
-61.1%
18.0K
Cost of Revenue
6.0K
-68.4%
19.0K
0
-100.0%
422.0K
+42100.0%
1.0K
Gross Profit
15.0K
+193.8%
-16000
-328.6%
7.0K
+101.7%
-415000
-2541.2%
17.0K
Operating Expenses
663.0K
-3.4%
686.0K
-70.1%
2.3M
+209.0%
743.0K
-23.0%
965.0K
R&D
35.0K
-53.9%
76.0K
+65.2%
46.0K
-58.2%
110.0K
+111.5%
52.0K
SG&A
252.0K
-2.7%
259.0K
-86.2%
1.9M
+631.1%
257.0K
-48.3%
497.0K
Operating Income
-648000
+7.7%
-702000
+69.3%
-2289000
-97.7%
-1158000
-22.2%
-948000
EBITDA
-364000
+12.9%
-418000
+79.1%
-2004000
-129.8%
-872000
-32.1%
-660000
Net Income
-644000
+8.0%
-700000
+69.4%
-2284000
-143.6%
5.2M
+454.9%
-1475000
EPS (Basic)
$-0.08
+38.5%
$-0.13
+48.0%
$-0.25
-133.8%
$0.74
+148.7%
$-1.52
EPS (Diluted)
$-0.08
+38.5%
$-0.13
+48.0%
$-0.25
-133.8%
$0.74
+148.7%
$-1.52
Shares (Diluted)
8.5M
+0.0%
8.5M
+0.0%
8.5M
+20.1%
7.1M
+636.6%
965.6K
Impact BioMedical (IBO) — Financials